Branch Roche, the company Genentech, sent to the U.S. regulatory agency an application for approval of anticancer drug Herceptin to treat patients with advanced gastric cancer.
According to Roche, the final phase of the study showed that the life expectancy of patients with advanced gastric cancer who have undergone chemotherapy with Herceptin, has increased.
Buy Cialis Tadalafil Order Cialis Online Cheap Cialis Generic Cialis 20mg NO Prescription
Viagra Online Sildenafil 100mg Buy Viagra Discount Canadian Pharmacy Generic Viagra Brand Name
Order Viagra Online Generic Levitra Cheap Cialis Drug Without Prescription
"We hope that Herceptin combined with chemotherapy will be the first drug of choice in the treatment of disseminated HER2-positive cancer of the stomach," - said Hal Barron (Hal Barron), Chief Medical Officer Genentech.
Roche said that the study showed that patients with gastric cancer at later stages of receiving Herceptin in combination with chemotherapy, overall survival significantly increased compared to receiving only chemotherapy, and unexpected side effects were observed.
According to Roche, stomach cancer is the second most common cause of cancer death in the world. Diagnosed each year more than 1 million cases of the disease.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.